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DifferentNa/Cl-dependent neurotransmitter transporters
of the SLC6a family have been shown to form dimers or oli-
gomers in both intracellular compartments and at the cell sur-
face. In contrast, the glycine transporters (GlyTs) GlyT1 and -2
have been reported to exist as monomers in the plasma mem-
brane based on hydrodynamic and native gel electrophoretic
studies. Here, we used cysteine substitution and oxidative cross-
linking to show that of GlyT1 andGlyT2 also formdimeric com-
plexes within the plasma membrane. GlyT oligomerization at
the cell surface was confirmed for both GlyT1 and GlyT2 by
fluorescence resonance energy transfermicroscopy. Endoglyco-
sidase treatment and surface biotinylation further revealed that
complex-glycosylatedGlyTs form dimers located at the cell sur-
face. Furthermore, substitution of tryptophan 469 of GlyT2 by
an arginine generated a transporter deficient in dimerization
thatwas retained intracellulary. Based on these results andGlyT
structuresmodeledbyusing the crystal structure of the bacterial
homolog LeuTAa, as a template, residues located within the
extracellular loop 3 and at the beginning of transmembrane
domain 6 are proposed to contribute to the dimerization inter-
face of GlyTs.
After presynaptic release and postsynaptic receptor activa-
tion, neurotransmitters have to be rapidly removed from the
synaptic cleft in order to allow synaptic transmission to proceed
with high spatial and temporal resolution. This is achieved by
neurotransmitter transporters located in the plasma mem-
brane of nerve terminals and adjacent glia cells. The family of
Na/Cl-dependent neurotransmitter transporters (SLC6a)
includes transporters for -aminobutyric acid (GAT1 to -3),5
glycine (GlyT1 and -2), dopamine (DAT), serotonin (SERT),
and norephinephrine (NET) (1–3). All of these transporters
display significant sequence similarity and share a common
membrane topology with 12 transmembrane segments (TMs), a
large second extracellular loop (EL2) connecting TM3 and TM4,
and cytoplasmic N- and C-terminal regions. Although the func-
tional unit of Na/Cl-dependent transporters is thought to be a
monomer, there is increasing evidence that these transporters
form dimers or even higher oligomers within the plasma mem-
brane (4).Oxidative treatment of theDATproduces dimers and
tetramers due to intermolecular disulfide bond formation
between two cysteine residues, Cys243 and Cys306, located
within TM4 and at the end of EL3, respectively (5, 6). Similarly,
chemical cross-linking and co-isolation of differentially tagged
transporter polypeptides has shown that the recombinant
SERT forms oligomers in human embryonic kidney (HEK) 293
cells (7, 8). Furthermore, for the GAT, DAT, and SERT it has
been shown that co-expression of the transporter polypeptides
fused to cyan fluorescent protein (CFP) with the respective yel-
low fluorescent protein (YFP)-tagged protein results in a Fo¨r-
ster resonance energy transfer (FRET) signal, suggesting that at
least dimers of these transporters exist (9, 10). A possible oli-
gomerization interface has been identified within TM2 of
GAT1, where both the disruption of a leucine heptadmotif and
substitution of polar amino acid residues caused intracellular
retention of the transporter and a loss of the FRET signal (11,
12). Also, x-ray crystallography of a bacterial ortholog of the
SLC6a transporter family, LeuTAa, revealed that this trans-
porter forms homodimers (13). Together, all of these data sup-
port the idea of Na/Cl-dependent neurotransmitter trans-
porters being oligomeric proteins.
There is, however, one reported exception from this rule, the
glycine transporters GlyT1 and GlyT2 (14–16). These trans-
porters mediate the uptake of the inhibitory neurotransmitter
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glycine from the extracellular space into glial cells (GlyT1) and
glycinergic neurons (GlyT2), respectively (3). Studies on GlyT-
deficient mice have shown that, after birth, GlyT1 is essential
for removing glycine from postsynaptic glycine receptors (17),
whereas GlyT2 is required for the reuptake of glycine into the
presynaptic terminal (18). Additionally, GlyT1 has been shown
to be involved in the regulation of glutamatergic neurotrans-
mission by controlling the occupancy of the glycine binding site
of the N-methyl-D-aspartate subtype of glutamate receptors
(19–21). Evidence for a predominantly monomeric state of
these transporters came from two independent studies that
failed to detect oligomeric GlyTs within the plasmamembrane.
Both hydrodynamic analysis of GlyT1 solubilized from rat spi-
nal cord (15) and affinity purification of surface-labeled recom-
binant GlyT1 and GlyT2 followed by blue native PAGE (14)
provided evidence for GlyTs being monomers at the cell sur-
face. Dimers and oligomers were only detected in intracellular
membranes and suggested to represent overexpression arti-
facts (14). Here, we used a combination of mutagenesis and
cysteine-mediated cross-linking as well as FRET analysis in liv-
ing cells to reexamine whether GlyTs form oligomers. Our data
indicate that these transporters are dimers not only in intracel-
lular compartments but also in the plasma membrane of HEK
293T cells.
EXPERIMENTAL PROCEDURES
Homology Modeling—The crystal structure of the bacterial
leucine transporter LeuTAa (Protein Data Bank code 2A65) was
used as a template to build a homologymodel of GlyT2. To this
end, the amino acid sequence of GlyT2 (accession no. Q761V0)
(22) was truncated at its N and C termini (residues 1–192 and
747–799, respectively), and the large EL2 (residues 313–364)
was deleted. The remaining sequence was aligned with LeuTAa
according to Yamashita et al. (13). Three-dimensional models
(10 structures) of GlyT1 and GlyT2 were built from the aligned
sequences on a Silicon Graphics Octane R12000 work station
using the MODELLER program (23). The models resulting in
the lowest root mean square deviation as compared with the
original LeuTAa structure were retained for analysis without
further refinement. Dimers of GlyT2 were created by juxtapos-
ing two transporter molecules using Thr464 as an anchoring
point. Figures were generated using PyMOL software (Delano
Scientific, Palo Alto, CA).
cDNA Constructs and Heterologous Expression—An expres-
sion construct for the human GlyT1c was kindly provided by
Dr. Katherine Fisher (Groton Laboratories, Pfizer, NY). The
GlyT2 cDNAwas isolated frommouse brain stemmRNAusing
standard cloning techniques. N-terminal heptahistidyl (His),
FLAG, and Myc tags were added by PCR-based mutagenesis.
After subcloning into the pcDNA3.1 vector (Invitrogen), the
respective substitutions were introduced by using the
QuikChange site-directedmutagenesis kit (Stratagene, La Jolla,
CA). For fluorescence analysis, the coding regions of GlyT1 and
GlyT2 were subcloned by PCR into pECFP-C1 or pEYFP-C1
(Clontech-Takara Bio Europe, Saint-Germain-en-Laye,
France) to create CFP- or YFP-tagged GlyT1 or GlyT2, respec-
tively. All constructs were verified by sequencing, and all sur-
face-expressed transporters were shown to be functional upon
heterologous expression in HEK 293T cells as revealed by
[3H]glycine uptake measurements (data not shown). An
expression construct for the human DAT (24) was kindly pro-
vided by Dr. Marc G. Caron (Duke University, Durham, NC),
and a membrane-bound form of YFP (25) was kindly provided
by Viacheslav Nikolaev (University of Wu¨rzburg, Germany).
HEK293T cells were grown inmodified Eagle’smedium sup-
plemented with glutamine (2 mM), 10% (v/v) fetal calf serum,
penicillin (50 units/ml), streptomycin (50 g/ml), and 50 M
-mercaptoethanol (all reagents from Invitrogen) at 37 °C in a
humidified 5% CO2 atmosphere. Cells were seeded on the day
prior to transfection into 6-well plates, and transfection was
performed at 70–85% confluence using the Polyfect transfec-
tion reagent (Qiagen, Hilden, Germany) according to the man-
ufacturer’s protocol. For GlyT1 expression, GripTite 293 cell
lines (Invitrogen) stably expressing GlyT1, GlyT1L343C, and
GlyT1C116A;L343C were generated and seeded 48 h before the
experiment.
Oxidative Cross-linking—Cross-linking experiments were
performed 48–72 h after transfection. Adherent cells were
washed twice with phosphate-buffered saline (PBS) or HEPES
buffered salt solution (130 mM NaCl, 1.3 mM KCl, 1.2 mM
MgSO4, 1.2 mM KH2PO4, 2 mM CaCl2, 10 mM glucose, 10 mM
NaOH/HEPES, pH 7.4) and incubated with 0.1–0.5mMCuSO4
and 0.8–2 mM o-phenanthroline (CuP) in PBS or HEPES buff-
ered salt solution for 10min at room temperature. The reaction
was stopped by removal of the reagent and incubation of the
cells with 10 mM N-ethylmaleimide in PBS for 15–20 min.
Western Blotting—Cells were lysed at 4 °C in lysis buffer con-
taining 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100,
0.25% (w/v) desoxycholate, 0.1% (w/v) SDS, 1 mM Pefabloc SC
(RocheApplied Science), and 50mMHEPES/Tris, pH 7.4. After
centrifugation for 15 min at 16,000 g, the protein content in
the supernatant was determined using the Bio-Rad Protein
assay (Bio-Rad, Munich, Germany), and 10 g of supernatant
protein were mixed with the appropriate volume of 4 nonre-
ducing loading buffer (Invitrogen) prior to separation by SDS-
PAGE on 3–8% Tris acetate gels (Invitrogen). Proteins were
transferred to either nitrocellulose (Whatman, Dassel, Ger-
many) or polyvinylidene fluoride (Amersham Biosciences)
membranes. The membranes were blocked in Tris-buffered
saline supplemented with 0.1% (w/v) Tween 20 and 5% (w/v)
nonfat milk powder for at least 30 min prior to a 30-min
incubation with primary antibodies directed against either the
N terminus of GlyT2 (polyclonal rabbit) (18), DAT (polyclonal
rabbit, Chemicon, Temecula, CA), theMyc epitope (polyclonal
rabbit, Abcam, Cambridge, UK) (all diluted 1:2000 in blocking
buffer), or the FLAG epitope (monoclonal mouse; Sigma; 4
g/ml). After washing with Tris-buffered saline containing
0.5% (w/v) Tween 20, membranes were incubated with horse-
radish peroxidase-conjugated goat anti-rabbit antibodies
(Invitrogen) and detected with the SuperSignal kit (Pierce).
Affinity Purification of His-tagged GlyT2—HEK 293T cells
were transfected with the indicated constructs and, 48 h later,
lysed in 100 mM sodium phosphate buffer, pH 8.0, containing
0.2% (w/v) dodecylmaltoside and 1mMPefabloc SC. The lysates
were centrifuged at 16,000 g for 15min, and 190g of super-
natant protein were incubated under continuous agitation with
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Ni2-NTA-agarose beads (Qiagen, Hilden, Germany) in the
aforementioned lysis buffer supplemented with 10 mM imidaz-
ole for 1 h at 4 °C. After washing with lysis buffer containing 30
mM imidazole and 0.075% (w/v) dodecylmaltoside, agarose-
bound proteins were eluted with 2 SDS loading buffer
(Invitrogen) for 10 min at 25 °C.
Functional Characterization of GlyT2—His-GlyT2WT or
His-GlyT2T464C was expressed in Xenopus laevis oocytes as
described previously (14). Glycine (30 M)-induced currents
were monitored using the two-electrode voltage clamp tech-
nique as described previously (26). The oocytes were treated
with 5 mM CuP for 15 min, and glycine-induced currents were
measured again. To analyze the efficacy of CuP-induced cross-
linking, His-tagged proteins were isolated from detergent
extracts of these oocytes as described (14) and subjected to
Western blot analysis. Dimers of 200 kDa were only seen after
CuP treatment of His-GlyT2T464C but not of untreated or His-
GlyT2WT-expressing cells (data not shown).
Surface Biotinylation—Surface biotinylation of transfected
HEK 293T cells with 1 mM NHS-SS-biotin (Pierce) was per-
formed essentially as described (27). After biotinylation, cell
lysates (50 g of protein) were incubated with streptavidin-
agarose beads (60l; Pierce) for 3 h at 4 °C. The beadswere then
washed three times with lysis buffer, and bound biotinylated
proteins were eluted by a 30-min incubation at 4 °C with 30 l
of 1 loading buffer (Invitrogen) supplemented with 0.6 mM
dithiothreitol. Aliquots of the lysates (15 g of protein) and
biotinylated fractions (30l) were then analyzed by SDS-PAGE
and Western blotting.
Fluorescence Resonance Energy Transfer—FRET signals (28)
were measured with an epifluorescencemicroscope (Carl Zeiss
Axiovert 200) using the “three-filter method” according to Xia
and Liu (29). Imageswere taken fromHEK293 cellsmaintained
and transfected as described previously (30) using a 63 oil
objective and a LUDL filter wheel that allows for rapid
exchange of filters. The systemwas equippedwith the following
fluorescence filters: CFP filter (ICFP; excitation  436 nm,
dichroism  455 nm, emission  480 nm), YFP filter (IYFP;
excitation  500 nm, dichroism  515 nm, emission  535
nm), and FRET filter (IFRET; excitation 436 nm, dichroism
455 nm, emission 535 nm). The acquisition of the imageswas
done with MetaMorph version 4.6. (Molecular Devices Corp.,
Downingtown, PA). Background fluorescence was subtracted
from all images, and fluorescence intensity wasmeasured at the
plasma membrane and in cytosolic regions in all images. To
calculate a normalized FRET signal (NFRET), we used the fol-
lowing equation,
NFRET
IFRET a IYFP b ICFP
IYFP ICFP
(Eq. 1)
where a and b represent the bleed-through values for YFP and
CFP. All NFRET values are expressed as means  S.E. Corrected
FRET (FRETc) images were obtained according to Ref. 31. Briefly,
after background subtraction from all three images, CFP and YFP
images were multiplied with their corresponding bleed-through
value. The following equation was used for the calculation of
FRETc images, FRETc FRET (bCFP) (a YFP).
ConfocalMicroscopy—GlyT cell surface expressionwas visu-
alized by confocal microscopy using a Zeiss Axiovert 200-LSM
510 confocal microscope (argon laser, 30 milliwatts; helium/
neon laser, 1 milliwatt) equipped with an oil immersion objec-
tive (Zeiss Plan-Neofluar 40/1.3). In brief, HEK 293 cells
transfected with the indicated construct were seeded onto glass
coverslips and examined 1 day later. In co-expression experi-
ments, fluorescent protein-tagged constructs were detected
with a band pass filter (475–525 nm) using the 458-nm (for
CFP, at 30–45% input power) or 488 nm (for YFP, at 8–10%
input power) laser lines. Plasma membranes were visualized
after the addition of 20l of trypan blue (0.05% (w/v) in PBS) at
an excitation wavelength of 543 nm with a long pass filter (585
nm). CFP and trypan blue images were captured sequentially,
and overlay images were produced with Zeiss imaging software
as described (32).
RESULTS
For the DAT, residue Cys306, located at the end of EL3
between TM5 and TM6, has been shown to be essential for
intermolecular disulfide bond formation upon oxidative treat-
ment (5). Sequence comparison revealed that in the GlyTs,
leucine and threonine residues are found at the homologous
positions (Leu343 in GlyT1c and Thr464 in GlyT2; Fig. 1A). To
assess whether these residues reside at the surfaces of the
respective transporter proteins andmight be close to a possible
dimerization interface, we generated amodel of GlyT2 by using
the crystal structure of LeuTAa as a template (13). Regions that
did not display significant homology to the LeuTAa protein, like
the intracellular N and C termini and the large EL2 between
TM3 and TM4, were deleted from the GlyT2 sequence to opti-
mize sequence alignment. The resultingGlyT2model showed a
rootmean square deviation of 3.62Å from theLeuTAa structure
when 498 of 504 pairwise C atoms were aligned (root mean
square deviation of 1.157 Å for 398 C atoms). In this model,
the side chain of Thr464 was located on the surface of the trans-
porter above the helix formed by TM11 (Fig. 1, B and C). Thus,
Thr464 might be close to a possible dimerization interface.
Apposition of two monomers at this interface created a GlyT2
dimer, in which the two Thr464 residues are in close proximity
(Fig. 1, B–E). This dimeric model suggests that, in addition to
interactions between the EL3 regions of the monomers, side
chains of TM11 could contribute to dimer stabilization. Like-
wise, in a similar model of GlyT1, Leu343, the amino acid resi-
due corresponding to Thr464 in GlyT2 and Cys306 in DAT, is
predicted to be localized at the surface of the transporter pro-
tein (data not shown).
To establish whether Thr464 is indeed located at a dimeriza-
tion interface of GlyT2, we replaced this residue by a cysteine in
order to examine whether GlyT2 oligomers can be stabilized by
intermolecular disulfide cross-linking, as reported for the DAT
(5). As controls, we generated two GlyT2 expression con-
structs, inwhich residues Lys462 andThr557 were substituted by
cysteines. According to ourmodel, both residues are unlikely to
face the proposed dimerization interface (Fig. 1, B–E). HEK
293T cells were transfected with these three cysteine-substi-
tuted GlyT2 constructs and analyzed for [3H]glycine uptake
activity and subcellular localization of GlyT2 immunoreactiv-
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ity. This did not reveal any significant differences as compared
withwild-typeGlyT2 (GlyT2WT; data not shown).Western blot
analysis of detergent extracts prepared from the transfected
cells confirmed that the mutant transporters were expressed in
amounts comparable with that obtained with the GlyT2WT
cDNA (Fig. 2C). Two bands of 65 and 90 kDa, which represent
the core-glycosylated and fully glycosylated transporter forms
(33), were seen with all three mutant proteins. An additional
band at about 155 kDa present in variable amounts presumably
corresponded to SDS-resistant dimers of immature transporter
polypeptides (14). Together, these data indicate that none of
the cysteine substitutions introduced affected the expression,
function, or plasmamembrane insertion ofGlyT2 inHEK293T
cells.
TheGlyT2T464CMutant Efficiently FormsDimers—Todeter-
mine whether position Thr464 is close to a potential dimeriza-
tion interface of GlyT2, HEK 293T cells transiently expressing
GlyT2WT, the GlyT2T464C mutant, or, as a control, DATWT
were treated with the oxidizing agent CuP, followed by deter-
gent extraction, nonreducing SDS-PAGE, and Western blot
analysis. With DATWT-expressing cells, CuP treatment
resulted in the appearance of a distinct band at 170 kDa in
addition to immunoreactive bands at 85 and 57 kDa (Fig. 2A),
which represent themature and immaturemonomeric forms of
this transporter (5). The 170 kDa
band corresponds in size to the pre-
viously described DATWT dimer
(5), thereby confirming a close
proximity of the Cys306 residues at
the dimer interface. Consistent with
previous findings (5), the formation
of DAT dimers by CuP was com-
pletely abolished when Cys306 was
replaced by an alanine (DATC306A;
Fig. 2A).
In contrast to these results
obtained with DATWT, CuP treat-
ment of cells expressing GlyT2WT
did not result in the formation of
SDS-resistantGlyT2 oligomers (Fig.
2B, left). However, CuP treatment of
GlyT2T464C-expressing cells gener-
ated a major GlyT2-immunoreac-
tive adduct of 200 kDa. This was
accompanied by a strong decrease
in the intensity of the 90 kDa band,
which represents the fully glycosy-
lated GlyT2monomer (Fig. 2B, left).
These results are consistent with
GlyT2T464C forming a dimer that is
cross-linked upon oxidative treat-
ment. To exclude the possibility
that this 200-kDa adduct represents
an unspecific aggregate induced by
CuP treatment, detergent extracts
from CuP-treated cells expressing
GlyT2T464C were supplemented
with -mercaptoethanol. This re-
ducing treatment resulted in a strong reduction of the 200 kDa
band and an increase in the intensity of the mature monomer
band at 90 kDa indicative of cleavage of the disulfide cross-link
(Fig. 2B, right). Notably, in contrast to what was found with
GlyT2T464C, CuP treatment of GlyT2T557C- or GlyT2K462C-ex-
pressing cells failed to produce the 200-kDa GlyT2 immunore-
active adduct (Fig. 2C). Thus, disulfide-mediated cross-linking
of the GlyT2T464C mutant is position-specific.
The functional consequences of CuP cross-linking were ana-
lyzed by measuring glycine-induced currents by two-electrode
voltage clamp in Xenopus oocytes expressing His-GlyT2WT or
His-GlyT2T464C before and after treatment with CuP. Applica-
tion of 30 M glycine induced currents of 76  8 pA for
GlyT2WT and 39  5 pA for GlyT2T464C (n  6). The smaller
current monitored for the GlyT2T464C mutant most likely
reflects a slightly reduced expression also seen inWestern blots
prepared from detergent extracts from the oocytes (data not
shown). After treatment with CuP, the currents recorded from
the same oocytes were not significantly reduced as compared
with the currents measured before cross-linking (reduction of
18  13% for His-GlyT2WT and of 15  12% for His-
GlyT2T464C, as compared with the untreated controls; p 0.5).
Similar to what was seen in HEK 293T cells, treatment of His-
GlyT2T464C but not His-GlyT2WT-expressing oocytes with
FIGURE 1.Model of the structure ofGlyT2.A, alignment of partial amino acid sequences of GlyT1, GlyT2, DAT,
and LeuTAa. B–E, homologymodel of GlyT2 based on the crystal structure of LeuTAa. B andC, the putativeGlyT2
dimer is depicted from the extracellular side (B) and within the plane of the membrane (C). Helices (cylinders)
are numbered following the LeuTAa nomenclature (13).D and E, close-up views of the dimer interface shown in
B and C. Residues substituted in this study are indicated.
GlyTs FormOligomers in the PlasmaMembrane
APRIL 18, 2008•VOLUME 283•NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 10981
CuP resulted in the appearance of a prominent GlyT2-immu-
noreactive band at 200 kDa (data not shown). Together, these
results are consistent with cross-linking of GlyT2 dimers by
CuP treatment not interfering with transporter function.
Very similar findings were also obtained with GlyT1. CuP
treatment of GlyT1WT stably expressing cells did not result in
the appearance of a immunoreactive band of higher molecular
weight. However, treatment of a GlyT1L343C-expressing cell
line produced a prominent immunoreactive band at 190 kDa.
To exclude the possibility that this dimer formation might
involve oxidation of the extracellular cysteine Cys116, we
repeated this experiment with a GlyT1C116A/L343C double
mutant. Again efficient formation of the 190-kDa adduct was
seen. Thus, Cys116 is not involved in oxidative cross-linking
(Fig. 2D). The slight increase in cross-linking efficacy seen in
cells expressing the GlyT1C116A/L343C double mutant most
likely reflects differences in expression levels between the stable
cell lines used. Taken together,
these data demonstrate that the
apparent molecular weight of both
GlyTs increase by a factor of about 2
upon treatment with CuP when
residues homologous to Cys306
within the DAT are substituted by
cysteines.
Transporters Cross-linked by
CuP Are Found in the Plasma
Membrane—Todetermine the sub-
cellular localization of the cross-
linked GlyT2T464C protein, we first
examined its glycosylation status.
Previous studies have shown that
complex-glycosylated GlyTs are
predominantly localized in the
plasma membrane, whereas imma-
ture core-glycosylated or nonglyco-
sylated transporter forms are
retained in intracellular compart-
ments (34, 35). When detergent
extracts prepared from CuP-treat-
ed HEK 293T cells expressing
GlyT2WT or theGlyT2T464Cmutant
were incubated with endoglycosi-
dase H, an enzyme that selectively
removes core glycosylations from
proteins, the apparent molecular
mass of the band at 90 kDa did not
change, but that of the immunore-
active 65 kDa band was reduced to
60 kDa (Fig. 3A). This confirms that
the 65-kDa polypeptide represents
the core-glycosylated formofGlyT2
(35). In addition, treatment with
endoglycosidase H reduced the
molecular mass of the 155 kDa
immunoreactive band to about 140
kDa, indicating that this GlyT2
complex is derived from immature,
and thus presumably intracellularly localized, GlyT2 protein
(14). In contrast, the immunoreactive band at 200 kDa gener-
ated upon CuP treatment of GlyT2T464C was insensitive to
treatment with endoglycosidase H (Fig. 3A). Thus, this cross-
linked GlyT2 adduct did not contain core-glycosylated pro-
teins. Incubation of the lysates from these cells with peptide:N-
glycosidase F reduced the apparent molecular masses of all
major immunoreactive bands to 140 and 60 kDa, respectively
(Fig. 3A). Together, these data support our conclusion that the
bands at 155 and 200 kDa represent GlyT2 dimers that differ in
their glycosylation status.
To directly assess which of the GlyT2 forms detected above
reside in the plasma membrane, we performed cell surface
biotinylation experiments with CuP-treated cells expressing
either GlyT2WT orGlyT2T464C (Fig. 3B). Subsequently, the bio-
tinylated surface proteins were separated from nonbiotinylated
intracellular proteins by using a streptavidin-agarose pull-
FIGURE 2. Oxidative cross-linking of cysteine-substituted GlyTs. A, Western blot of detergent extracts of
HEK293T cells expressingDATWTorDATC306A. The cellswere treatedwithPBS () or CuP (), prior to SDS-PAGE
and immunoblottingwith aDAT-specific antibody. Bands assigned to the immaturemonomer (E), themature
monomer (), and its dimer () are indicated. B (left), HEK 293T cells were transfected with GlyT2WT or
GlyT2T464C and treatedwith CuP (), or PBS (), prior to detergent extraction andWestern blot analysis with a
GlyT2-specific antibody. Right, detergent extracts from CuP-treated cells expressing GlyT2T464C were supple-
mentedwith-mercaptoethanol (100mM)or left untreated, prior toWesternblot analysiswith aGlyT2-specific
antibody. C, Western blot of detergent extracts prepared from HEK 293T cells expressing Myc- or His-tagged
GlyT2WT and theMyc-GlyT2T464C,Myc-GlyTK462C, orMyc-GlyT2T557Cmutants. Prior to detergent extraction, cells
were treated with CuP () or PBS (), as indicated. D, GripTite 293 cells expressing FLAG-tagged GlyT1,
GlyT1L343C, or GlyT1C116A/L343Cwere treatedwith CuP () or PBS (), prior to detergent extraction andWestern
blot analysis with an anti-FLAG antibody. Note that both GlyTs formed adducts of higher molecular weight
upon treatment with CuP only when cysteine-substituted. Different transporter forms are indicated:F, imma-
ture monomer;, mature monomer; FF, immature dimer;, mature dimer. Filled symbols, GlyT2; shaded
symbols, GlyT1.
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down approach. Western blot analysis of the bound biotiny-
lated protein fraction revealed that the bands at 90 and 200 kDa
representing mature monomeric transporter and the cross-
linked putative GlyT2T464C homodimer, respectively, were
enriched within the surface fraction. Thus, a major fraction of
the CuP-cross-linked GlyT2T464C protein is localized in the
plasma membrane. The apparently increased 90 kDa/200 kDa
ratio seen in the GlyT2T464C eluate might reflect cleavage of
some of the cross-linked dimer during affinity isolation, due to
inclusion of a low concentration of dithiothreitol being
required for efficient elution from the streptavidin-agarose
beads (see “Experimental Procedures”).
GlyT Oligomerization Monitored by FRET—To further cor-
roborate the existence of GlyT dimers in the plasmamembrane
by an independent technique, we employed FRET microscopy
(28) using the three-filter method according to Xia and Liu (29)
that allows us to quantitatively monitor protein oligomeriza-
tion. Visualization of protein oligomerization in intact cells was
achieved by the method of Sorkin et al. (31), which generates
FRETc images. Cytosolic proteins known to lack or only spuri-
ously formoligomeric complexes, enhancedCFP and enhanced
YFP, were used as background controls. To provide a reference
for membrane protein oligomerization, we co-expressed CFP-
and YFP-tagged versions of the human DAT (C-DAT and
Y-DAT, respectively), which has been shown to homo-oli-
gomerize by both FRET microscopy and biochemical
approaches (5, 10, 36). In addition, we used SERT tagged with
CFP and YFP on its cytoplasmic N and C termini, respectively
(C-SERT-Y) (i.e. a transporter construct predicted to produce
strong homotypic FRET signals) (37).
Expression of C-SERT-Y and coexpression of C-DAT and
Y-DAT resulted in enriched plasma membrane fluorescence
(Fig. 4A and supplemental Fig. S1, respectively) and, as
expected, robust NFRET signals (0.712  0.024 and 0.262 
0.017, respectively; Fig. 4C). Similarly, expression of fluores-
cently labeled GlyTs resulted in predominant plasma mem-
brane fluorescence (Fig. 4A and supplemental Fig. S1). NFRET
values obtainedwithC-GlyT2 andY-GlyT2 (0.268 0.019; Fig.
4C) were similar to those found with C-DAT and Y-DAT. This
confirms that GlyT2 forms oligomers in living cells. Although
co-expression of C-GlyT1 and Y-GlyT1 produced a somewhat
lower NFRET value (0.206  0.030; Fig. 4C), this value was sig-
nificantly higher than that obtained with different membrane
proteins employed as controls (p  0.001; analysis of variance
with Bonferroni correction). In accordance with the data
shown in Fig. 3 and observations made with other members of
the Na/Cl-dependent neurotransmitter transporter family
(9, 10), we also detected GlyT oligomers by FRET at intracellu-
lar locations (Fig. 4A; “cytosolic” NFRET values: GlyT1, 0.196
0.012; GlyT2, 0.283  0.016). To validate our FRET data, we
also employed a membrane-bound form of YFP that predomi-
nantly inserts into the plasma membrane (25); co-expression
with C-GlyT2 yielded an NFRET value of 0.152 0.018 (Fig. 4C
and supplemental Fig. S1). Apparently, this membrane-at-
tached YFP can serve as an acceptor for CFP fluorophores
attached to proteins integral to the plasma membrane; indeed,
some spurious FRET signal was faintly visible upon co-expres-
sion with C-GlyT2 (Fig. 4B and supplemental Fig. S1). There-
fore, we co-expressed both GlyT1 and GlyT2 with another
unrelated membrane protein, the G-protein-coupled receptor
for dopamine subtype 2, which had already served as a negative
control in FRET studies on SERT andGAT1 (9). Similar towhat
was observed upon co-expression with the corticotropin-re-
leasing factor receptor (CRFR1-Y; see Fig. 7D), co-expression of
either C-GlyT1 or C-GlyT2 with dopamine subtype 2-Y
resulted in significantly lower plasma membrane NFRET values
as compared with those obtained upon coexpressing CFP-
FIGURE 3. The CuP-induced GlyT2 adduct is complex-glycosylated and
localized at the cell surface. A, detergent extracts of CuP ()-treated HEK
293T cells transfected with His-GlyT2WT or His-GlyT2T464C were incubated
with endoglycosidase H (Endo H) or peptide:N-glycosidase F (PNGase F), as
indicated, and analyzed byWestern blotting using a GlyT2-specific antibody.
B, HEK 293T cells transfectedwith His-GlyT2WT or His-GlyT2T464C were treated
with CuP (), washed, and subjected to surface biotinylation. Aliquots of the
detergent extracts prepared from these cells (total) aswell as the eluates from
the streptavidin-agarosebeads containing thebiotinylatedproteins (surface)
were analyzed by Western blotting analysis with GlyT2-specific antibodies.
Different transporter forms are indicated as follows. F, immature monomer;
V, deglycosylated monomer; , mature monomer; FF, immature dimer;
VV, deglycosylated dimer;, mature dimer.
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and YFP-tagged GlyTs (0.137  0.012 and 0.152  0.015,
respectively; p  0.001; see Fig. 4, A–C, and supplemental
Fig. S1). Together, these results confirm that both GlyTs
oligomerize in intracellular compartments as well as at the
plasma membrane.
Dimer Formation Revealed by Co-isolation of Differently
Tagged GlyT2 Polypeptide—To prove that the putative
GlyT2T464C dimer of 200 kDa contains twoGlyT2polypeptides,
we used a co-isolation approach. To this end, we first singly
transfected plasmids encoding His-GlyT2T464C, Myc-
GlyT2WT, and Myc-GlyT2T464C into HEK 293T cells. Western
blot analysis of detergent extracts prepared from the trans-
fected cells with a GlyT2-specific antibody demonstrated that
all of these tagged GlyT2 proteins were expressed at compara-
ble levels (Fig. 5A, lanes C1, L1, and L2) and formed the previ-
ously described immunoreactive bands of 65 kDa correspond-
ing to the core-glycosylated protein of 90 kDa, representing the
mature monomer, and, in varying amounts, the 155-kDa dimer
of the core-glycosylated GlyT2 (14). Upon coexpression of the
His- andMyc-tagged transporters, nomajor changes in expres-
sion were detected (Fig. 5A, lanes L3 and L4). After CuP treat-
ment, GlyT2 adducts of 200 kDa were only seen in cells trans-
fected with Myc- and/or His-GlyT2T464C mutant constructs
(Fig. 5A, lanes C2 and L6–L8), whereas samples from CuP-
treated Myc-GlyT2WT-expressing cells failed to produce this
band (lane L5). Reprobing of the blots with aMyc-specific anti-
body revealed that both Myc-tagged transporters were
expressed at similar levels when expressed individually (lanes L9
and L10) or together with His-GlyT2T464C (lanes L11 and L12).
Upon CuP treatment, Myc immunoreactivity was incorporated
into the 200 kDa band only in cells expressing the Myc-
GlyT2T464C mutant (Fig. 5, lanes L14 and L16) but not Myc-
GlyT2WT (lanes L13 and L15). Therefore, the GlyT2-immunore-
active 200 kDa band seen in lane L7 represents a GlyT2 dimer
consisting exclusively of His-GlyT2T464C.
Subsequently, we used Ni2-NTA-agarose beads to isolate
His-GlyT2 and associated proteins from the detergent extracts
of the single- and double-transfected cells. The agarose-bound
proteins were then eluted and subjected to Western blot anal-
ysis. Fig. 5B shows that GlyT2 protein was efficiently affinity-
isolated from detergent extracts prepared from His-GlyT2-ex-
pressing cells (lanes E3, E4, E7, and E8). No GlyT2
immunoreactivity was found in samples isolated from cells
transfected only with Myc-tagged GlyT2 constructs (lanes E1,
E2, E5, and E6), consistent with a specific binding of the His tag
to the Ni2-NTA-agarose. Reprobing of the blot membranes
with a Myc-specific antibody revealed that affinity purification
on Ni2-NTA-agarose co-isolated core-glycosylated mono-
meric and dimericMyc-taggedGlyT2 protein (65 and 155 kDa)
from cells expressing both His-GlyT2T464C and Myc-GlyT2WT
orMyc-GlyT2T464C and that this co-isolation was independent
of CuP treatment (Fig. 5B, lanes E11, E12, E15, and E16). This
result confirms that core-glycosylated GlyT2 forms stable oli-
gomers intracellularly (see also Ref. 14 and Fig. 3), thus allowing
the co-isolation of Myc-GlyT2 protein. Furthermore, incorpo-
ration of Myc immunoreactivity into the 155-kDa band sug-
gests that this band is indeed a GlyT2 dimer, which contains
both His-GlyT2T464C and Myc-GlyT2 protein.
Upon cotransfection of the His-GlyT2T464C mutant with
Myc-GlyT2WT followed by CuP treatment, Myc immunoreac-
tivity was not found at 200 kDa (Fig. 5B, lane E15), although
FIGURE 4. GlyT oligomerization demonstrated by FRET in intact cells.
A, HEK 293T cells were transiently transfected with cDNAs encoding CFP- or
YFP-tagged proteins as indicated. Two days after transfection, epifluores-
cence microscopy was performed; the first and second columns show images
obtained with CFP and YFP filter sets, and the third column displays a cor-
rected and inverted FRET image (FRETc). A look-up tableof the color codeused
is presented in the first and fourth image, third column (negative and positive
control, respectively). All images shown are representative of 3–7 experi-
ments. In all images, background fluorescence was subtracted. Scale bar, 10
m.B, corrected and inverted FRET imagesofHEK293T cells transiently trans-
fectedwith the indicatedconstructs. For a look-up tableof the color codeused,
see Fig. 5A. Images are representatives of at least three experiments. C, nor-
malized FRET efficiencies (NFRET values) are given for cells expressing the fol-
lowing constructs: enhanced cyan fluorescent protein (ECFP) and enhanced
yellow fluorescent protein (EYFP) (n  124), C-GlyT1 and D2R-Y (n  79),
C-GlyT2 and D2R-Y (n  50), C-GlyT2b and membrane-bound YFP (membr.
YFP;n54), C-GlyT1 andY-GlyT1 (n102), andC-GlyT2 andY-GlyT2 (n73),
respectively. Similarly, HEK 293 cells expressing C-DAT and Y-DAT (n 30) as
well as C-SERT-Y (n  102; see also Ref. 37) were examined. Data represent
means S.E.; ***, p 0.001; analysis of variance, post hocBonferroni’s test for
multiple comparisons.
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some reactive 200-kDa complex had been isolated (compare
lanes L7 and E7). An additional Myc-immunoreactive band at
220 kDa (lane E15, *) did not react with theGlyT2 antibody and
thus represents an unknown cross-reactive protein complex
presumably derived from endogenous HEK 293T cell proteins.
Incorporation of Myc immunoreactivity into the cross-linked
200-kDa GlyT2 complex was only observed when His-
GlyT2T464C and Myc-GlyT2T464C were coexpressed (Fig. 5,
lane E16). These data prove that the band at 200 kDa represents
a GlyT2 dimer, which is covalently stabilized by the CuP-in-
duced disulfide bond. Since dimer formation of complex-glyco-
sylatedGlyT2 proteins required the presence of theT464C sub-
stitution in both tagged proteins, disulfide bonding apparently
involves Cys464 exclusively, consistent with transporter dimer-
ization involving identical interfaces.
GlyT2 Can Form Hetero-oli-
gomers with Other Members of the
SLC6a Family—Given the high
degree of overall homology between
the different transporter subtypes in
the SLC6a family, we surmised that
they might also form hetero-oligo-
meric complexes. Hence, we
searched for resonance energy
transfer betweenGlyT2 andDATor
GAT1. Co-expression of C-DAT
with Y-GlyT2 resulted in a FRET
signal at the plasmamembrane level
(Fig. 6A; NFRET  0.25  0.02),
which was comparable with that
detected with homotypic GlyT2-
or DAT-expressing cells (NFRET 
0.31 0.03 and 0.26 0.02, respec-
tively; Fig. 6B). Similar results were
obtained with cells expressing
C-GAT1 and Y-GlyT2 (NFRET 
0.28  0.01; Fig. 6, A and B), con-
firming that GlyT2 forms hetero-
oligomers with other members of
the SLC6a family.
To further investigate whether
this oligomerization is mediated via
an interface close to threonine 464
in GlyT2, we performed co-isola-
tion experiments with cells ex-
pressing both GlyT2T464C and/or
His-DATWTwith andwithout CuP-
induced cross-linking. As expected,
Western blot analysis of detergent
extracts from these cells revealed
GlyT2 immunoreactivity only in
cells transfected with the
GlyT2T464C expression construct
(Fig. 6C, lanes L2, L3, L5, and L6),
although coexpression with His-
DATWT resulted in a reduction of
GlyT2T464C expression. Similarly,
DAT immunoreactivity was only
detected in lanes loaded with detergent extracts from His-
DATWT-transfected cells (Fig. 6C, lanes L7, L8, L10, and L11).
Dimers of the expected sizes were detected after treatment of
the cells with CuP (Fig. 6C, lanes L5, L6, L10, and L11). How-
ever, coexpression of His-DATWT and GlyT2T464C failed to
produce additional GlyT2- and DAT-immunoreactive bands,
demonstrating that the predominant dimers formed were
homodimers consisting of His-DATWT or GlyT2T464C. These
detergent extracts were subsequently subjected to Ni2-NTA-
agarose affinity purification of His-tagged proteins. Western
blots of the respective eluates showed that DAT immunoreac-
tivity was efficiently enriched in samples from His-DATWT-
expressing cells (Fig. 6C, lanes E7, E8, E10, and E11). GlyT2
immunoreactivity was only detected in eluates from cells co-
expressing His-DATWT and GlyT2T464C (Fig. 6C, lanes E2 and
FIGURE 5. The 200-kDa CuP-induced GlyT2 adduct is a homodimer. HEK 293T cells cotransfected with His-
GlyT2T464C andeitherMyc-GlyT2WT orMyc-GlyT2T464Cwere treatedwithCuP () or PBS () as indicated.A, aliquots
of detergent extracts prepared from the treated cells were sequentially analyzed by Western blotting using the
GlyT2-specific antibody (lanes C1,C2, and L1–L8) and, after removal of boundantibody, an anti-Myc antibody (lanes
L9–L16). Note the presence ofmature GlyT2 dimers in lanes L6–L8 and L14 and L16, respectively. B, aliquots of the
extracts used in A were affinity-purified on Ni2-NTA-agarose. Blots prepared from the eluates were first
probed with the GlyT2 antibody (lanes E1–E8) and, after removal of the bound antibodies, restained with a
Myc-specific antibody (lanes E9–E16). Note that aMyc-immunoreactive 200-kDa adductwas isolated only after
CuP treatment of cells expressing both His-GlyT2T464C andMyc-GlyT2T464C (lane E16). The different transporter
forms are indicated:F, immature monomer;, mature monomer;FF, immature dimer;, mature dimer.
An asterisk indicates an unspecific band detected with the anti-Myc antibody.
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E5), whereas the other lanes were devoid of specific signals,
indicating that co-isolation was dependent on His-DATWT.
Thus, these results confirm the data obtained by FRETmicros-
copy. Surprisingly, both lanes showed a band of 90 kDa,
resembling the mature GlyT2T464C
monomer,whereas immature forms
of the transporter (i.e. the intracel-
lular immature monomer and its
dimer) were excluded from this
fraction. In addition to this band,
eluates prepared from GlyT2T464C/
His-DATWT-expressing cells pro-
duced another GlyT2-immunore-
active band at 200 kDa after
treatment with CuP. Its position
corresponds to that of the mature
GlyT2 dimer (Fig. 6C, lane E5) and
is clearly distinct from theDAT-im-
munoreactive bands in the same
sample (Fig. 6C, lane E11). Taken
together, these data reveal that the
mature GlyT2T464C protein can
form a dimer or higher order oli-
gomer with His-DATWT. How-
ever, these heteromeric
GlyT2T464C-DATWT complexes
form only with low efficacy and can-
not be cross-linked byCuP, suggest-
ing that their structure differs from
that of the respective homodimers.
A Mutation Impairing Dimeriza-
tion Results in Intracellular Reten-
tion of GlyT2—In order to identify
residues other than Thr464 that
might contribute to the putative
dimer interface of GlyT2, we exam-
ined our structural model for neigh-
boring residues. A candidate resi-
due likely to contribute to the
dimerization interface was found to
be residue Trp469, located after the
end of EL3 at the beginning of TM6.
In the model shown in Fig. 1, this
residue is predicted to contact the
neighboring transporter monomer.
We therefore generated a double
mutant C-GlyT2T464C/W469R, in
which the hydrophobic tryptophan
residue had been replaced by a
charged arginine side chain. This
substitution caused intracellular
retention of mutant GlyT2, as
observed by confocal microscopy
employing trypan blue to specifi-
cally stain the plasma membrane of
living cells (Fig. 7A). In contrast,
GlyT2s containing the single substi-
tution T464C or T457K were
expressed at the cell surface to an extent indistinguishable from
that seen with GlyT2WT (not shown, but see Fig. 7B). Both
C-GlyT2T464C and C-GlyT2T457K colocalized with
Y-GlyT2WT at the plasma membrane upon co-expression,
FIGURE 6.Heteromer formationofGlyT2withDATandGAT1.A, HEK 293T cells were transiently transfected
with cDNAsencodingCFP- or YFP-taggedproteins, as indicated. Twodays after transfection, FRETc valueswere
obtained. A look-up table of the color code used is given in the upper right. NFRET values (percentage) normal-
ized toC-GlyT2/Y-GlyT2-expressing cells (100%) are given for cells expressing ECFP andEYFP (n16), C-GATWT
and Y-GlyT2 (n  34), C-DATWT and Y-GlyT2WT (n  34), C-DATWT and Y-DATWT (n  30), and C-GlyT2WT and
Y-GlyT2WT (n 18), respectively. Note that NFRET values obtained from C-GlyT2
WT/Y-GlyT2WT-expressing cells
were not significantly different statistically from that of cells expressing C-GATWT/YGlyT2WT or C-DATWT/Y-
GlyT2WT (p0.05). Data representmeans S.E. analysis of variancewithpost hocBonferroni’s test formultiple
comparison.C, HEK293Tcellswere transfectedwithHis-DATWT,GlyT2T464C, or both constructs and treatedwith
CuP () or PBS (), and detergent extracts prepared from these cells were analyzed byWestern blotting with
the GlyT2 antibody (lanes L1–L6), followed, after removal of the bound antibodies, by an anti-DAT antibody
(lanes L7–L12). Aliquots of the detergent extractswere subjected toNi2-NTA-basedpurification of His-tagged
proteins. The eluates from the beadswere sequentially analyzed byWestern blotting using first the anti-GlyT2
(lanes E1–E6) and then the anti-DAT antibody (lanes E7–E12). Note that in the eluates, GlyT2 immunoreactivity
was only found in fractions derived from His-DATWT- and GlyT2T464C-co-expressing cells and that both the
mature monomer and the cross-linked dimer were present in these fractions. Different transporter forms are
indicated. F, immature monomer; , mature monomer; FF, immature dimer; , mature dimer. Filled
symbols, GlyT2; open symbols, DAT.
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whereas C-GlyT2T464C/W469R colocalized only weakly in intra-
cellular compartments (Fig. 7B). Importantly, this double
mutant was incapable of retaining Y-GlyT2WT intracellularly.
In analogy to retention assays employed with SERT (37) and
DAT (38), this served as the first indication that this double
mutant dimerizes only poorly. Subsequently, we co-expressed
C-GlyT2T464C/W469R with Y-GlyT2WT and performed FRET
microscopy. Fig. 7, C andD, shows clearly that the FRET signal
in intracellular compartments was greatly reduced (NFRET 
42 5% ofNFRETC-GlyT2WT/Y-GlyT2WT) as compared with
that observed in C-GlyT2WT and Y-GlyT2WT (not shown, but
see Fig. 4) but similar to that found in C-GlyT2WT- and
CRFR1-Y co-expressing cells (Fig. 7, D and E). In contrast,
FRETmicroscopy performed with C-GlyT2T464C co-expressed
with Y-GlyT2WT or transfections of CFP- and YFP-tagged ver-
sions of GlyT2T457K revealed FRET signals comparable with
those seen with CFP- and YFP-tagged GlyT2WT (NFRET 
105 5% and NFRET 94 4% (Fig. 7, C and D); see also Fig.
S1). We also induced intracellular retention of Y-GlyT2WT by
co-expressing Sar1dn, a T39Nmutant of Sar1a that impairs the
correct formation of vesicles mediating endoplasmic reticulum
export of protein cargo (39), in order to exclude the possibility
that low FRET signals resulted from a lack of colocalization.
HEK 293 cells triple-transfected with Y-GlyT2WT,
C-GlyT2T464C/W469R, and Sar1dn showed intracellular reten-
tion of both the wild-type transporter and the double mutant
(Fig. 7C). Although massive intracellular accumulation of the
two proteins was observed, we failed to detect a specific intra-
cellular FRET signal in these cells (NFRET  41  5% as com-
pared with NFRET of C-GlyT2WT- and Y-GlyT2WT-expressing
cells; Fig. 7E). This result further indicates that the GlyT2T464C/
W469R mutant is unable to oligomerize and is retained
intracellularly.
To biochemically prove that GlyT2T464C/W469R is indeed
unable to dimerize, aMyc-tagged version of themutant protein
was co- expressed with His-GlyT2T464C. Western blot analysis
of detergent extracts prepared from cells expressing His-
GlyT2T464C, Myc-GlyT2T464C/W469R, or both constructs
FIGURE 7. Disruption of GlyT2 dimerization leads to intracellular retention. HEK 293T cells were transiently transfected with C-GlyT2WT and C-GlyT2
mutants as indicated and examined using a confocal microscope (A and B) or an epifluorescence microscope (C). A, colocalization of C-GlyT2T464C/W469R and
C-GlyT2WT with trypan blue; fluorescence emitted by CFP and trypan blue is shown in green and red, respectively. B, colocalization of C-GlyT2 mutants and
Y-GlyT2WT, as indicated. Thepictures shown inA andB are representative of four or five images captured inparallel from the same transfection; the experiments
were repeated two or three times with independent transfections. C, representative images obtained with CFP and YFP filter sets; the third column displays
FRETc for HEK 293T cells expressing C-GlyT2
T464C/W469R and Y-GlyT2WT (upper lane) or C-GlyT2T464C/W469R and Y-GlyT2WT without and with dominant negative
Sar1dn (lower lanes). D, NFRET values, normalized to C-GlyT2
WT/Y-GlyT2WT-expressing cells, are indicated for cells co-expressing C-GlyT2WT and CRFR1-Y (n
30), C-GlyT2T464C/W469R and YFP-GlyT2WT (n 54), C-GlyT2T464C and Y-GlyT2WT (n 67), and C-GlyT2WT and Y-GlyT2WT (n 62), respectively. Data represent
means S.E. of three experimental days. E,NFRET values (percentage) normalized to C-GlyT2
WT/Y-GlyT2WT expressing cells are indicated for cells co-expressing
C-GlyT2WT and CRFR1-Y and pcDNA3.1 (n 14), C-GlyT2T464C/W469R and Y-GlyT2WT and Sar1dn (n 17), C-GlyT2T464C/W469R and Y-GlyT2WT and pcDNA3.1 (n
16), and C-GlyT2WT and Y-GlyT2WT and pcDNA3.1 (n 25). Data representmeans S.E. of two experimental days. ***, p 0.001; analysis of variance, post hoc
Bonferroni’s test for multiple comparisons.
GlyTs FormOligomers in the PlasmaMembrane
APRIL 18, 2008•VOLUME 283•NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 10987
revealed strong GlyT2 immunoreactivity in all three samples
(Fig. 8A, lanes L1–L3). Upon CuP treatment, a strong GlyT2-
immunoreactive band at 200 kDa was seen in His-GlyT2T464C-
expressing (lanes L5 and L6) but not Myc-GlyT2T464C/W469R-
expressing cells (lane L4). Reprobing of these blots with aMyc-
specific antibody revealed immunoreactive bands in all lanes
loaded with extracts prepared fromMyc-GlyT2T464C/W469R-ex-
pressing cells (Fig. 8, lanes L7, L8, L10, and L11). Consistent
with our findings using confocalmicroscopy, we failed to detect
any mature forms of the transporter; only the intracellular
monomer or its dimer could be detected in these lanes. Aliquots
of these extracts were then subjected to Ni2-NTA affinity
purification of His-GlyT2T464C. Probing Western blots pre-
pared from these eluates with the GlyT2 antibody revealed
immunoreactive bands for the intracellular monomer and its
dimer, the mature monomer, and, in samples prepared from
CuP-treated cells, also the mature dimer, in the His-
GlyT2T464C-containing samples (Fig. 8B, lanes E2, E3, E5, and
E6). Reprobing of these Western blots with Myc-specific anti-
bodies consistently failed to produce any specific band (Fig. 8B,
lanes E7–E12), indicating that even in intracellular compart-
ments, Myc-GlyT2T464C/W469R does not interact with His-
GlyT2T464C.We therefore conclude that EL3 and the beginning
of TM6 (i.e. the region containing the crucial residues Thr464
and Trp469) is important for GlyT2 dimerization.
DISCUSSION
In this study, we used two inde-
pendent approaches, cysteine-me-
diated cross-linking and FRET
microscopy, to show that upon
heterologous expression both
GlyT2 and GlyT1 form dimers in
the plasma membrane. Compari-
son with other members of the
SLC6a family suggests that GlyTs
oligomerize via an interface that is
conserved between SLC6amembers.
Based on oxidative cross-linking
data obtained with the DAT and
GlyTmodels generated by using the
crystal structure of the bacterial
homolog LeuTAa as a template, we
focused on EL3 linking TM5 and
TM6 as contributing to a potential
oligomerization interface. This loop
is located at the outer surface of the
transporter monomer above TM11
and, in the DAT, contains residue
Cys306, which is responsible for oxi-
dative cross-linking of the trans-
porter dimer (6). Here, modeling
predicted the GlyT positions
homologous to Cys306 of the DAT,
Thr464 in GlyT2, and Leu343 in
GlyT1c to similarly face a conserved
dimerization interface of the trans-
porters that might involve residues
within EL3, the beginning of TM6, and possibly TM11. Indeed,
upon cysteine substitution and oxidizing treatment,
GlyT2T464C and GlyT1L343C were efficiently cross-linked to
200- and 190-kDa adducts, respectively. In contrast, neither
GlyT1WT nor GlyT2WT nor other cysteine-substituted GlyT2
proteins (GlyT2K462C and GlyT2T557C) produced the 200 kDa
band uponCuP treatment. Furthermore, in the case of GlyT1, a
double mutant (GlyT1C116A/L343C), in which a second extracel-
lular cysteine at position 116 had been replaced by alanine, was
found to be as efficiently cross-linked as GlyT1L343C. All of
these data are consistent with a high positional specificity of
cysteine-mediated cross-linking at an interface formed by EL3.
Cross-linking did not significantly affect transporter function,
as demonstrated by recordings from GlyT2T464C-expressing
oocytes prior to and after CuP treatment. This is consistent
with the idea that the dimerization interface does not undergo
major structural rearrangements during the transport cycle.
Also, reduction of the cross-linked transporter dimer with
-mercaptoethanol resulted in a cleavage of the 200-kDa
adduct, indicating that CuP treatment did not induce aggrega-
tion of the GlyT2T464C mutant.
The differential sensitivity to endoglycosidaseH and peptide:
N-glycosidase F treatment as well as our surface biotinylation
experiments indicated that the CuP-cross-linked cysteine-sub-
stituted GlyT2 adducts of 200 kDa correspond to dimers com-
FIGURE 8. GlyT2T464C/W469R does not form complexes with GlyT2T464C. A, HEK 293T cells were transfected
with His-GlyT2T464C, Myc-GlyT2T464C/W469R, or both constructs. After 48 h, the cells were treatedwith CuP () or
PBS (). Detergent extracts prepared from these cellswere sequentially analyzedbyWesternblottingwith first
the anti-GlyT2 antibody and then anti-Myc antibody. B, aliquots of the detergent extracts were subjected to
Ni2-NTA affinity purification of His-tagged proteins. Western blots of the eluates were analyzed by using first
anti-GlyT2 and then anti-Myc antibodies. Note that no Myc immunoreactivity was found in the eluates pre-
pared from cells co-expressing His-GlyT2T464C and Myc-GlyT2T464C/W469R, although purification of His-
GlyT2T464C was successful, as indicated by GlyT2 immunoreactivity (lower panel, left). The different transporter
forms are indicated as follows. F, immature monomer; , mature monomer; FF, immature dimer; ,
mature dimer.
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posed of complex-glycosylated, mature transporter polypep-
tides located in the plasmamembrane. Since detection of these
200 kDa GlyT2 dimers by SDS-PAGE was stringently depend-
ent on CuP cross-linking, its constituent monomers appeared
to be only loosely associated. This is consistent with blue native
PAGE experiments in which we failed to detect electrophore-
sis-resistant GlyT oligomers at the cell surface of both oocytes
andHEK 293 cells (see Ref. 14).6 Also, in sedimentation studies,
detergent-solubilized GlyT1 behaves as a monomeric protein
(40). In line with our previous data (14), we found dimers of
immature core-glycosylated transporters that were localized
intracellularly, as revealed by their inaccessibility to surface
biotinylation. Notably, these intracellular GlyT complexes dis-
played partial resistance toward dissociation by SDS, and CuP
treatment did not increase their abundance. Thismay in part be
due to inefficient permeation of CuP into the cytosol. Alterna-
tively, a different orientation of the EL3 cysteine in the imma-
ture GlyT2T464C polypeptide might impede cross-linking. The
differences noted in the SDS resistance of mature versus imma-
ture GlyT2 complexesmight even reflect distinct steps in intra-
cellular transporter processing. The complex carbohydrate side
chains that are added and modified posttranslationally might
weaken the interactions between dimerization interfaces and
thereby result in a detergent-sensitive dimer upon plasma
membrane incorporation. Indeed, evidence for a role of glyco-
sylation in transporter processing and stability has been
obtained in studies showing reduced transport activity upon
mutation of the transporters’ N-glycosylation sites (41, 42).
Direct support for the existence of GlyT oligomers in living
cells comes from our FRET data. Consistent with our biochem-
ical results, a specific FRET signal was seen upon co-expression
of CFP- and YFP-tagged GlyT1 or GlyT2 polypeptides in both
the plasmamembrane and intracellular compartments. During
revision of this manuscript, a very similar result with GlyT1 has
been reported by others (43). Differences found in FRET signal
intensities between the two transporters (see Fig. 4) may reflect
differences in expression levels and/or membrane targeting as
well as different orientations of the fluorophores, due to the
different sizes of the N-terminal domains to which the fluoro-
phores were attached.
That the CuP-induced GlyT complexes are indeed
homodimers was proven here by co-isolation of the differen-
tially tagged transporter polypeptides. This and its size of about
200 kDa indicate that the cross-linkedGlyT2 dimer contains no
other additional polypeptides. Since our co-isolation protocol
produced dimers onlywhen bothmonomers carried theT464C
substitution, we conclude that this particular cysteine is
required and sufficient for complex stabilization by intermolec-
ular disulfide bonding. Our results indicate that the transporter
monomers dimerize via an interface that is conserved between
the GlyTs and the DAT (5, 6) and possibly also other SLC6a
family members. For the DAT, it has been reported that a sec-
ond cysteine, located within TM4, also allows intermolecular
cross-linking. This cysteine is conserved between DAT and the
GlyTs (Cys393 in GlyT2 and Cys220 in GlyT1, respectively).
However, under our experimental conditions, we consistently
failed to detect the formation of any higher molecular weight
adductswith the respectivewild-type constructs. This indicates
that within the GlyTs, this cysteine is not accessible for inter-
molecular cross-linking.
In addition to the homodimers described above, heteromer
formation betweenGlyT2 andGAT1, orDAT,was seen by both
FRET analysis and co-purification of GlyT2T464C immunoreac-
tivity with His-DATWT on Ni2-NTA-agarose. However, this
co-isolation was completely independent of CuP cross-linking,
since we failed to detect any cross-linked heterodimers in elu-
ates fromNi2-NTA columns. Furthermore, we only found the
fully glycosylated GlyT2 polypeptide in these eluates, whereas
immature transporter forms were excluded from this fraction;
this suggests that heterodimerization occurs at the plasma
membrane. Together with the observation that even the cross-
linked GlyT2T464C dimer was co-isolated with His-DATWT, we
conclude that CuP-induced intermolecular cross-linking is
selective for each SLC6a transporter subtype. This conclusion
implies that the interaction of His-DATWT with the complex
glycosylated GlyT2 monomer and dimer involves interaction
sites distinct from that mediating dimer formation. It is
tempting to speculate that such interaction sites could allow
the formation of higher order transporter oligomers at sites
of high transporter density, such as the presynaptic terminal
membrane.
Based on our modeling data, we propose that the SLC6a
transporters dimerize via an interface to which the EL3 region
and the extracellular end of TM6 contribute. Support for this
proposal comes from our analysis of the GlyT2T464C/W469R
doublemutant, which carries a positive charge instead of a tryp-
tophan at the extracellular end of TM6 (see Fig. 1, D and E).
This mutant transporter protein was found to be deficient in
dimerization as shown by (i) the low of FRET signal resulting
upon co-expression with GlyT2WT, (ii) impaired co-isolation
with the GlyT2T464C mutant, and (iii) the inability to retain
GlyT2WT intracellularly.We also tried to identify determinants
for dimerizationwithin TM11, which according to ourmodel is
closest to the dimerization interface. However, substitutions of
aromatic residues within TM11 by branched aliphatic amino
acids failed to reduce CuP cross-linking of the respective
mutants,7 indicating that these side chains are not specific
determinants of transporter oligomerization. Taken together,
our data suggest that GlyTs dimerize via an interface involving
EL3 and the extracellular end of TM6. Disruption of this inter-
face results in dimerization- deficient transporter protein that
is retained intracellularly.
In addition to the dimerization interface defined by EL3 and
the extracellular end of TM6, other putative oligomerization
domains have been described in earlier studies of other SLC6a
family members. First, a leucine heptad motif within TM2 of
GAT1 has been found to be essential for both plasma mem-
brane insertion and oligomerization of the transporter (11).
According to our structural models, these leucines as well as
glutamate and tyrosine residues that also have beenproposed to
6 I. Bartholoma¨us and A. Nicke, unpublished data. 7 V. Eulenburg, unpublished data.
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be important for oligomerization (12) are at least partially bur-
ied within the transporter structure and thus unlikely to
directly participate in oligomer formation (see also Ref. 4). Pre-
sumably, substitutions at these positions lead to structural
changes that indirectly disturb the dimerization interface. Sim-
ilarly, the glycophorin A homologymotif, which has been iden-
tified in TM6 of the DAT in close proximity to EL3 (38), is
predicted to lie within the central core of the transporter close
to the substrate binding site and thus is unlikely to directly
contribute to monomer interactions. Presumably, these muta-
tions affect folding or proper tertiary structure acquisition and
thus cause a loss of function and/or intracellular retention of
the transporters. Also, it is noteworthy that LeuTAa has been
crystallized in dimeric structural form. In this bacterial homo-
log, a homomeric dimerization interface is formed by TM9 and
TM12 (i.e. a region that, based on retention assays with partial
transporter constructs, has also been suggested to serve as a
dimerization domain in the human SERT) (37).
Oligomerization of SLC6a transporter proteins has beenpro-
posed to be important for both posttranslational processing
and transporter function at the plasma membrane (4, 8). In
different studies, truncated or mutated transporter fragments,
which are retained intracellularly, have been shown to exert
dominant negative effects on co-expressed full-length trans-
porters. For example, the expression of SERT fragments con-
taining TM1 and -2, TM5 and -6, or TM11 and -12 resulted in
intracellular retention of the co-expressed full-length SERT
(37). In the case of the NET, a heterozygous mutation (A457P),
which is causal for orthostatic intolerance in human patients,
has been found to cause a 90% reduction of NET activity (44).
Similar effects have also been described for GlyT2. There, a
disease mutation that is associated with human hyperekplexia
(S510R), resulted in intracellular retention of the co-expressed
wild-type transporter (45). Taken together, the existence of
such dominant mutations corroborates the conclusions
reached in this study. Similar to other members of the SLC6a
family, GlyTs form dimers, and dimer formation appears to be
a prerequisite for correct transporter processing and surface
delivery. At the cell surface, transporter oligomerization may
have functional consequences (8). For monoamine transport-
ers, oligomerization has been suggested to support their reverse
operation (30). Although the stabilization of the GlyT2T464C
dimer by CuP-induced cross-linking did not affect transport
activity, we cannot exclude modulatory effects of dimerization
on transport activity, since the dimerization-deficient
GlyT2T464C/W469R mutant was retained intracellularly and
hence not accessible to functional characterization. Clearly,
further experiments are required to unravel the precise mech-
anisms by which oligomerization affects transporter surface
expression and/or activity.
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